Search / Trial NCT00001541

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Nov 3, 1999

Trial Information

Current as of October 18, 2024

Completed

Keywords

Vasculitis Inflammation Bronchoscopy Cytokines Inflammatory Mediators Wegener's Granulomatosis

Description

Wegener's granulomatosis is a systemic vasculitis in which parenchymal and/or endobronchial inflammation frequently occur. The purpose of this investigation is to analyze bronchial and bronchoalveolar lavage fluid in patients with Wegener's granulomatosis for the presence of immunoregulatory mediators and pro-inflammatory cytokines. We will also be examining mucosal biopsies in these patients to define the histologic changes, the phenotype of infiltrating leukocytes, and the pattern of adhesion molecule expression that may be present. Such studies could lead to an improved understanding of ...

Gender

ALL

Eligibility criteria

  • INCLUSION CRITERIA:
  • Diagnosis of Wegener's granulomatosis based on clinical and histological characteristics.
  • Age between 18-75 years.
  • Bronchoscopy is required as part of their standard medical care.
  • FEV1 is greater than 55 percent of FVC.
  • O2 saturation is greater than 90 percent.
  • EXCLUSION CRITERIA:
  • FEV1 is less than 55% of FVC.
  • O2 saturation is less than 90%.
  • Abnormal PT, PTT, or platelet count less than 50.
  • History of adverse reaction to lidocaine or other local anesthetics.
  • Pregnancy.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0